Dupilumab for dermatitis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Eczema

Why this status

  1. 14 Dec 2010: Trial registered, NCT01259323

The trials

NCT01259323: Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

State
Completed
Phase
Phase 1
People
30 taking part
Started
Dec 2010
Primary completion
Jul 2012
Arms
Cohort 1, Cohort 2, Cohort 3
Results
None posted
  1. 14 Dec 2010: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Also known as Dupixent, Dupilumab (SAR231893), Dupilumab - Discontinuation, Dupilumab - Dose Reduction, Dupilumab - Standard Dose, Dupilumab Only Product, Dupilumab SAR231893, Dupilumab step-down, Dupilumab therapy, REGN3500 + Dupilumab Combo, Vanicream- Experienced Dupilumab.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.